Consun Pharmaceutical Group Past Earnings Performance
Past criteria checks 5/6
Consun Pharmaceutical Group has been growing earnings at an average annual rate of 21.7%, while the Pharmaceuticals industry saw earnings growing at 5.9% annually. Revenues have been growing at an average rate of 8.5% per year. Consun Pharmaceutical Group's return on equity is 20.1%, and it has net margins of 30.3%.
Key information
21.7%
Earnings growth rate
23.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 5.6% |
| Revenue growth rate | 8.5% |
| Return on equity | 20.1% |
| Net Margin | 30.3% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Consun Pharmaceutical Group (HKG:1681) Is Increasing Its Dividend To CN¥0.30
Jun 01
Consun Pharmaceutical Group (HKG:1681) Has A Rock Solid Balance Sheet
May 04Consun Pharmaceutical Group (HKG:1681) Will Pay A Dividend Of HK$0.20
Apr 28Consun Pharmaceutical Group (HKG:1681) Has Announced A Dividend Of HK$0.20
Apr 07Consun Pharmaceutical Group (HKG:1681) Has Announced That It Will Be Increasing Its Dividend To HK$0.10
Aug 26Consun Pharmaceutical Group (HKG:1681) Seems To Use Debt Rather Sparingly
Apr 21Does It Make Sense To Buy Consun Pharmaceutical Group Limited (HKG:1681) For Its Yield?
Mar 17Here's Why Consun Pharmaceutical Group's (HKG:1681) Statutory Earnings Are Arguably Too Conservative
Feb 19How Much Did Consun Pharmaceutical Group's(HKG:1681) Shareholders Earn From Share Price Movements Over The Last Three Years?
Jan 29Could The Consun Pharmaceutical Group Limited (HKG:1681) Ownership Structure Tell Us Something Useful?
Jan 08
Consun Pharmaceutical Group (HKG:1681) Seems To Use Debt Quite Sensibly
Dec 18Should Consun Pharmaceutical Group Limited (HKG:1681) Be Part Of Your Income Portfolio?
Nov 18Revenue & Expenses BreakdownBeta
How Consun Pharmaceutical Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 2,590 | 785 | 1,155 | 0 |
| 30 Sep 23 | 2,528 | 759 | 1,124 | 0 |
| 30 Jun 23 | 2,466 | 734 | 1,093 | 0 |
| 31 Mar 23 | 2,403 | 708 | 1,078 | 0 |
| 31 Dec 22 | 2,340 | 683 | 1,062 | 0 |
| 30 Sep 22 | 2,246 | 660 | 1,008 | 0 |
| 30 Jun 22 | 2,152 | 636 | 954 | 0 |
| 31 Mar 22 | 2,098 | 613 | 918 | 0 |
| 31 Dec 21 | 2,045 | 590 | 882 | 0 |
| 30 Sep 21 | 1,959 | 565 | 855 | 0 |
| 30 Jun 21 | 1,874 | 541 | 827 | 0 |
| 31 Mar 21 | 1,813 | 520 | 801 | 0 |
| 31 Dec 20 | 1,753 | 499 | 775 | 0 |
| 30 Sep 20 | 1,653 | 269 | 754 | 0 |
| 30 Jun 20 | 1,553 | 39 | 733 | 0 |
| 31 Mar 20 | 1,641 | 60 | 752 | 0 |
| 31 Dec 19 | 1,728 | 80 | 771 | 0 |
| 30 Sep 19 | 1,822 | 288 | 762 | 0 |
| 30 Jun 19 | 1,916 | 496 | 754 | 0 |
| 31 Mar 19 | 1,880 | 481 | 746 | 0 |
| 31 Dec 18 | 1,844 | 465 | 738 | 0 |
| 30 Sep 18 | 1,802 | 448 | 733 | 0 |
| 30 Jun 18 | 1,760 | 430 | 728 | 0 |
| 31 Mar 18 | 1,710 | 413 | 716 | 0 |
| 31 Dec 17 | 1,660 | 396 | 704 | 0 |
| 30 Sep 17 | 1,601 | 372 | 680 | 0 |
| 30 Jun 17 | 1,541 | 347 | 656 | 0 |
| 31 Mar 17 | 1,382 | 327 | 586 | 0 |
| 31 Dec 16 | 1,223 | 308 | 516 | 0 |
| 30 Sep 16 | 1,060 | 291 | 454 | 0 |
| 30 Jun 16 | 896 | 274 | 392 | 0 |
| 31 Mar 16 | 863 | 262 | 387 | 0 |
| 31 Dec 15 | 831 | 250 | 382 | 0 |
| 30 Sep 15 | 814 | 246 | 372 | 0 |
| 30 Jun 15 | 798 | 242 | 362 | 0 |
| 31 Mar 15 | 764 | 226 | 353 | 0 |
| 31 Dec 14 | 731 | 211 | 345 | 0 |
| 30 Sep 14 | 697 | 198 | 330 | 0 |
| 30 Jun 14 | 664 | 185 | 315 | 0 |
| 31 Mar 14 | 618 | 169 | 285 | 0 |
| 31 Dec 13 | 572 | 153 | 256 | 0 |
| 30 Sep 13 | 538 | 144 | 232 | 0 |
| 30 Jun 13 | 504 | 135 | 209 | 0 |
Quality Earnings: 1681 has high quality earnings.
Growing Profit Margin: 1681's current net profit margins (30.3%) are higher than last year (29.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 1681's earnings have grown significantly by 21.7% per year over the past 5 years.
Accelerating Growth: 1681's earnings growth over the past year (14.9%) is below its 5-year average (21.7% per year).
Earnings vs Industry: 1681 earnings growth over the past year (14.9%) exceeded the Pharmaceuticals industry 1.3%.
Return on Equity
High ROE: 1681's Return on Equity (20.1%) is considered high.